148 related articles for article (PubMed ID: 25835095)
21. Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations.
Oak JS; Ohgami RS
Curr Med Res Opin; 2017 Apr; 33(4):781-782. PubMed ID: 28097878
[No Abstract] [Full Text] [Related]
22. ASXL1/2 mutations and myeloid malignancies.
Medina EA; Delma CR; Yang FC
J Hematol Oncol; 2022 Sep; 15(1):127. PubMed ID: 36068610
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding.
Burgess AE; Kleffmann T; Mace PD
J Mol Biol; 2021 Nov; 433(22):167242. PubMed ID: 34536441
[TBL] [Abstract][Full Text] [Related]
24. The role of ASXL1 mutations and ASXL1 CircRNAs in cancer.
Jafarbeik-Iravani N; Kolahdozan S; Esmaeili R
Biomarkers; 2024 Feb; 29(1):1-6. PubMed ID: 38193494
[TBL] [Abstract][Full Text] [Related]
25. Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions.
Peng H; Begg GE; Schultz DC; Friedman JR; Jensen DE; Speicher DW; Rauscher FJ
J Mol Biol; 2000 Feb; 295(5):1139-62. PubMed ID: 10653693
[TBL] [Abstract][Full Text] [Related]
26. ASXL1 Gene in AML.
Hurtado R; Guirales F; Tirado CA
J Assoc Genet Technol; 2021; 47(2):60-68. PubMed ID: 34140438
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic Regulator ASXL2: Structure, Function and its Predictive Value in Diseases.
Li M; Xu L; Zhang R; Dong C
Curr Protein Pept Sci; 2023; 24(1):22-30. PubMed ID: 36503466
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family.
Fisher CL; Randazzo F; Humphries RK; Brock HW
Gene; 2006 Mar; 369():109-18. PubMed ID: 16412590
[TBL] [Abstract][Full Text] [Related]
29. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938
[TBL] [Abstract][Full Text] [Related]
30. Step out of the groove: epigenetic gene control systems and engineered transcription factors.
Verschure PJ; Visser AE; Rots MG
Adv Genet; 2006; 56():163-204. PubMed ID: 16735158
[TBL] [Abstract][Full Text] [Related]
31. Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3).
Ayoub MC; Anderson JT; Russell BE; Wilson RB
Front Neurosci; 2023; 17():1244176. PubMed ID: 38027485
[TBL] [Abstract][Full Text] [Related]
32. Domains involved in ETO and human N-CoR interaction and ETO transcription repression.
Wang J; Wang M; Liu JM
Leuk Res; 2004 Apr; 28(4):409-14. PubMed ID: 15109542
[TBL] [Abstract][Full Text] [Related]
33. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.
Spensberger D; Delwel R
FEBS Lett; 2008 Aug; 582(18):2761-7. PubMed ID: 18619962
[TBL] [Abstract][Full Text] [Related]
34. Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Ropero S; Ballestar E; Alaminos M; Arango D; Schwartz S; Esteller M
Oncogene; 2008 Jun; 27(28):4008-12. PubMed ID: 18264134
[TBL] [Abstract][Full Text] [Related]
35. ARX homeodomain mutations abolish DNA binding and lead to a loss of transcriptional repression.
Shoubridge C; Tan MH; Seiboth G; Gécz J
Hum Mol Genet; 2012 Apr; 21(7):1639-47. PubMed ID: 22194193
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
37. The role of mutations in epigenetic regulators in myeloid malignancies.
Woods BA; Levine RL
Immunol Rev; 2015 Jan; 263(1):22-35. PubMed ID: 25510269
[TBL] [Abstract][Full Text] [Related]
38. PHD fingers: epigenetic effectors and potential drug targets.
Musselman CA; Kutateladze TG
Mol Interv; 2009 Dec; 9(6):314-23. PubMed ID: 20048137
[TBL] [Abstract][Full Text] [Related]
39. Additional sex combs-like family genes are required for normal cardiovascular development.
McGinley AL; Li Y; Deliu Z; Wang QT
Genesis; 2014 Jul; 52(7):671-86. PubMed ID: 24860998
[TBL] [Abstract][Full Text] [Related]
40. Functional domains of the TGF-beta-inducible transcription factor Tieg3 and detection of two putative nuclear localization signals within the zinc finger DNA-binding domain.
Spittau B; Wang Z; Boinska D; Krieglstein K
J Cell Biochem; 2007 Jun; 101(3):712-22. PubMed ID: 17252542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
